341 related articles for article (PubMed ID: 23524017)
1. Bronchodilation and safety of supratherapeutic doses of salbutamol or ipratropium bromide added to single dose GSK961081 in patients with moderate to severe COPD.
Norris V; Ambery C
Pulm Pharmacol Ther; 2013 Oct; 26(5):574-80. PubMed ID: 23524017
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics of GSK961081, a bi-functional molecule, in patients with COPD.
Bateman ED; Kornmann O; Ambery C; Norris V
Pulm Pharmacol Ther; 2013 Oct; 26(5):581-7. PubMed ID: 23538170
[TBL] [Abstract][Full Text] [Related]
3. Long-acting dual bronchodilator therapy (indacaterol/glycopyrronium) versus nebulized short-acting dual bronchodilator (salbutamol/ipratropium) in chronic obstructive pulmonary disease: A double-blind, randomized, placebo-controlled trial.
van Geffen WH; Carpaij OA; Westbroek LF; Seigers D; Niemeijer A; Vonk JM; Kerstjens HAM
Respir Med; 2020 Sep; 171():106064. PubMed ID: 32917359
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies.
Quinn D; Barnes CN; Yates W; Bourdet DL; Moran EJ; Potgieter P; Nicholls A; Haumann B; Singh D
Pulm Pharmacol Ther; 2018 Feb; 48():71-79. PubMed ID: 28987804
[TBL] [Abstract][Full Text] [Related]
5. Acute effects of higher than standard doses of salbutamol and ipratropium on tiotropium-induced bronchodilation in patients with stable COPD.
Cazzola M; Santus P; D'Adda A; Pizzolato S; Di Marco F; Centanni S
Pulm Pharmacol Ther; 2009 Jun; 22(3):177-82. PubMed ID: 19038356
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of ipratropium bromide/salbutamol sulphate administered in a hydrofluoroalkane metered-dose inhaler for the treatment of COPD.
Bhattacharya A; Bhargava S; Singh V; Talwar D; Whig J; Rebello J; Purandare S; Gogtay J
Int J Chron Obstruct Pulmon Dis; 2016; 11():1469-76. PubMed ID: 27418820
[TBL] [Abstract][Full Text] [Related]
7. A double-blind crossover study comparing the safety and efficacy of three weeks of Flu/Sal 250/50 bid plus albuterol 180 ug prn q4 hours to Flu/Sal 250/50 bid plus albuterol/Ipratropium bromide 2 puffs prn q4 hours in patients with chronic obstructive pulmonary disease.
Balkissoon R; Make B
COPD; 2008 Aug; 5(4):221-7. PubMed ID: 18671147
[TBL] [Abstract][Full Text] [Related]
8. Nebulized formoterol effect on bronchodilation and satisfaction in COPD patients compared to QID ipratropium/albuterol MDI.
Sutherland ER; Brazinsky S; Feldman G; McGinty J; Tomlinson L; Denis-Mize K
Curr Med Res Opin; 2009 Mar; 25(3):653-61. PubMed ID: 19232039
[TBL] [Abstract][Full Text] [Related]
9. Bronchodilating effect of combined therapy with ipratropium bromide and ondansetron in patients with COPD.
Pauwels R; Joos GF; Fogarty C; Faiferman I; Hirschberg S; Vessey R; Wouters EF
Pulm Pharmacol Ther; 2008; 21(2):385-92. PubMed ID: 18023600
[TBL] [Abstract][Full Text] [Related]
10. A new class of bronchodilator improves lung function in COPD: a trial with GSK961081.
Wielders PL; Ludwig-Sengpiel A; Locantore N; Baggen S; Chan R; Riley JH
Eur Respir J; 2013 Oct; 42(4):972-81. PubMed ID: 23429913
[TBL] [Abstract][Full Text] [Related]
11. Daily variation in lung function in COPD patients with combined albuterol and ipratropium: results from a 4-week, randomized, crossover study.
Singh D; Zhu CQ; Sharma S; Church A; Kalberg CJ
Pulm Pharmacol Ther; 2015 Apr; 31():85-91. PubMed ID: 25197005
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
Kerwin EM; Gotfried MH; Lawrence D; Lassen C; Kramer B
Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
[TBL] [Abstract][Full Text] [Related]
13. The short-term bronchodilator effects of the dual phosphodiesterase 3 and 4 inhibitor RPL554 in COPD.
Singh D; Abbott-Banner K; Bengtsson T; Newman K
Eur Respir J; 2018 Nov; 52(5):. PubMed ID: 30166326
[TBL] [Abstract][Full Text] [Related]
14. A dose-ranging study of the bronchodilator effects of abediterol (LAS100977), a long-acting β2-adrenergic agonist, in asthma; a Phase II, randomized study.
Singh D; Pujol H; Ribera A; Seoane B; Massana E; Astbury C; Ruiz S; de Miquel G
BMC Pulm Med; 2014 Nov; 14():176. PubMed ID: 25398689
[TBL] [Abstract][Full Text] [Related]
15. An evaluation of nebulized levalbuterol in stable COPD.
Datta D; Vitale A; Lahiri B; ZuWallack R
Chest; 2003 Sep; 124(3):844-9. PubMed ID: 12970007
[TBL] [Abstract][Full Text] [Related]
16. Bronchodilator effects, pharmacokinetics and safety of PSX1002-GB, a novel glycopyrronium bromide formulation, in COPD patients; a randomised crossover study.
Singh D; Ravi A; Reid F; Buck H; O'Connor G; Down G
Pulm Pharmacol Ther; 2016 Apr; 37():9-14. PubMed ID: 26827913
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of single therapeutic and supratherapeutic doses of indacaterol versus salmeterol and salbutamol in patients with asthma.
Brookman LJ; Knowles LJ; Barbier M; Elharrar B; Fuhr R; Pascoe S
Curr Med Res Opin; 2007 Dec; 23(12):3113-22. PubMed ID: 17999782
[TBL] [Abstract][Full Text] [Related]
18. Bronchodilator reversibility in patients with COPD revisited: short-term reproducibility.
Pascoe S; Wu W; Zhu CQ; Singh D
Int J Chron Obstruct Pulmon Dis; 2016; 11():2035-40. PubMed ID: 27621609
[TBL] [Abstract][Full Text] [Related]
19. 24-hour bronchodilation following a single dose of the novel β(2)-agonist olodaterol in COPD.
van Noord JA; Smeets JJ; Drenth BM; Rascher J; Pivovarova A; Hamilton AL; Cornelissen PJ
Pulm Pharmacol Ther; 2011 Dec; 24(6):666-72. PubMed ID: 21839850
[TBL] [Abstract][Full Text] [Related]
20. Does a single dose of the phosphodiesterase 4 inhibitor, cilomilast (15 mg), induce bronchodilation in patients with chronic obstructive pulmonary disease?
Grootendorst DC; Gauw SA; Baan R; Kelly J; Murdoch RD; Sterk PJ; Rabe KF
Pulm Pharmacol Ther; 2003; 16(2):115-20. PubMed ID: 12670781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
